Nebenwirkungen · Xelevia
Xelevia 25 mg film-coated tablets Xelevia 50 mg film-coated tablets Xelevia 100 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 7–8
HOS-117572 · Präparat HOS-094641
7 TECOS Cardiovascular Safety Study The Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) included 7,332 patients treated with sitagliptin, 100 mg daily (or 50 mg daily if the baseline eGFR was ≥ 30 and < 50 mL/min/1.73 m2), and 7,339 patients treated with placebo in the intention-to-treat population. Both treatments were added to usual care targeting regional standards for HbA1c and CV risk factors. The overall incidence of serious adverse events in patients receiving sitagliptin was similar to that in patients receiving placebo.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-01T17:33:00Z · SHA-256 f08aea892d6a7b9cf75b34f4b4074c9f6b71db0d601e841798224bb137a5083a · Passage d0ef4083cd51daf8f183ded80c98565bc0014917d21aebcee1d256fa12d51ce2 · Zeichen 5555–6108 im Abschnitt